Skip to main content

What are the new drugs used for multiple sclerosis (MS)?

Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 29, 2024.

Official Answer by Drugs.com

The newest drugs for the treatment of multiple sclerosis include Briumvi, Ponvory, Kesimpta, Bafiertam, Zeposia, Vumerity, Mavenclad, Mayzent, and Ocrevus.

Multiple sclerosis (MS) is a neurological disease that affects the brain and spinal cord. In MS, the body's immune system attacks the protective myelin sheaths that cover nerve fibers, causing areas of scarring called sclerosis.

MS is a lifelong illness. It can follow one of several different patterns:

Latest FDA Approvals for Multiple Sclerosis

Brand Generic Name Company Approved Type Indications
Ocrevus Zunovo ocrelizumab and hyaluronidase-ocsq
(injection)
Genentech, Inc. September 13, 2024 CD20-directed cytolytic antibody and hyaluronidase combination RRMS, SPMS, PPMS
Briumvi ublituximab-xiiy
(injection)
TG Therapeutics, Inc. December 28, 2022 CD20-directed cytolytic monoclonal antibody RRMS, SPMS
Ponvory ponesimod
(tablets)
Janssen Pharmaceuticals, Inc. March 18, 2021 sphingosine 1-phosphate receptor modulator RRMS, SPMS
Kesimpta ofatumumab
(injection)
Novartis August 20, 2020 CD20-directed cytolytic monoclonal antibody RRMS, SPMS
Bafiertam monomethyl fumarate (delayed-release capsules) Banner Life Sciences LLC April 28, 2020 oral fumarate RRMS, SPMS
Zeposia ozanimod (capsules) Bristol-Myers Squibb Company March 25, 2020 sphingosine 1-phosphate receptor modulator RRMS, SPMS
Vumerity diroximel fumarate
(delayed-release capsules)
Biogen October 29, 2019 oral fumarate RRMS, SPMS
Mavenclad cladribine (tablets) EMD Serono, Inc. March 29, 2019 purine antimetabolite RRMS, SPMS
Mayzent siponimod (tablets) Novartis March 26, 2019 sphingosine-1-phosphate receptor modulator RRMS, SPMS
Ocrevus ocrelizumab (injection) Genentech, Inc. March 28, 2017 CD20-directed cytolytic monoclonal antibody RRMS, SPMS, PPMS
Zinbryta (withdrawn from market March 2018) daclizumab (injection) Biogen May 27, 2016 interleukin-2 receptor blocking antibody RRMS
Lemtrada alemtuzumab (injection) Genzyme Corporation November 14, 2014 CD52-directed cytolytic monoclonal antibody RRMS, SPMS
Plegridy peginterferon beta-1a (injection) Biogen August 15, 2014 pegylated interferon beta RRMS, SPMS
Tecfidera dimethyl fumarate (capsules) Biogen March 27, 2013 Nrf2 pathway activator RRMS, SPMS
Aubagio teriflunomide (tablets) Sanofi September 12, 2012 pyrimidine synthesis inhibitor RRMS, SPMS
Gilenya fingolimod (capsules) Novartis September 21, 2010 sphingosine 1-phosphate receptor modulator RRMS, SPMS
Tysabri natalizumab (injection) Biogen November 23, 2004 integrin receptor antagonist RRMS, SPMS

Related questions

Drugs in Development for Multiple Sclerosis

Brand Name Generic Name Company Development Stage Type Condition
laquinimod Teva Pharmaceuticals Phase 2/3 CNS-active immunomodulator RRMS, PPMS

Read next

What are the early signs of multiple sclerosis?

Some of the early signs of multiple sclerosis (MS) include weakness or numbness in one or more limbs; tremor or abnormal, uncoordinated movements while walking; slurred speech, or dizziness; double vision or the painful loss of vision in one eye; or long-lasting fatigue. Continue reading

Prednisone: What are 12 Things You Should Know?

Prednisone first came onto the market over sixty years ago and is still going strong. But did you know that this common drug used for a variety of different conditions also has some pretty serious side effects as well? Continue reading

Is Kesimpta better than Ocrevus?

In patients with relapsing forms of multiple sclerosis, Kesimpta (ofatumumab) is thought to be more effective than Ocrevus (ocrelizumab) in some ways, but no clinical trials have directly compared the two drugs

Ocrevus is the only one of the two drugs approved to treat primary progressive multiple sclerosis Continue reading

See also:

Related medical questions

Related support groups